$347.94
▼ $-5.34
(-1.51%)
Vol 1.6M
11
Quality Score
ok
Deep Check
2/5
ok
Rev ✓
NI ✓
>IPO ✗
Mkt Cap
$176.3B
P/E
25.2
ROE
96.2%
Margin
19.5%
D/E
567.49
Beta
0.46
Div Yield
3.08%
52W
$257–$346
Wall Street Consensus
43 analysts · Apr 20266
Strong Buy
15
Buy
19
Hold
2
Sell
1
Strong Sell
48.8%
Buy Rating
Price Chart
Similar Stocks
About Amgen Inc. - Common Stock
Amgen — провідна біотехнологічна компанія, що спеціалізується на розробці та виробництві ліків для лікування серйозних захворювань. Компанія займає лідерські позиції на ринку біологічних препаратів, зокрема в онкології, кардіології та неврології. Ключові конкурентні переваги Amgen включають потужний науково-дослідний потенціал, диверсифікований портфель продуктів та глобальну мережу дистрибуції.
Earnings
Beat rate: 100.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $4.83 | $5.29 | +$0.46 |
| Sep 2025 | $5.11 | $5.64 | +$0.53 |
| Jun 2025 | $5.39 | $6.02 | +$0.63 |
| Mar 2025 | $4.39 | $4.90 | +$0.51 |
Quarterly Revenue & Earnings
| Quarter | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|
| Revenue | $9.1B | $8.1B | $9.2B | $9.6B | $9.9B |
| Net Income | $627.0M | $1.7B | $1.4B | $3.2B | $1.3B |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 97.9% | 97.9% | 97.9% | 97.9% | 96.2% | 96.2% |
| P/E (TTM) | 22.68 | 24.22 | 23.49 | 24.27 | 26.01 | 25.16 |
| Net Margin | 15.6% | 19.0% | 19.0% | 19.0% | 19.5% | 19.5% |
| Gross Margin | 70.9% | 69.7% | 69.7% | 69.7% | 72.1% | 72.1% |
| D/E Ratio | 756.65 | 756.65 | 756.65 | 756.65 | 567.49 | 567.49 |
| Current Ratio | 1.31 | 1.31 | 1.31 | 1.31 | 1.28 | 1.28 |
Key Ratios
ROA (TTM)
7.8%
P/S (TTM)
4.90
P/B
23.8
EPS (TTM)
$12.94
CF/Share
$20.77
Rev Growth 3Y
+8.8%
52W High
$346.38
52W Low
$257.05
$257.05
52-Week Range
$346.38
Financial Health
Free Cash Flow
$961.0M
Net Debt
$45.5B
Cash
$9.1B
Total Debt
$54.6B
As of Dec 31, 2025
How does AMGN compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
AMGN valuation vs Biotechnology peers
P/E ratio
25.2
▲
34%
above
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
4.9
▼
62%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
23.8
▲
869%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
3.1%
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
AMGN profitability vs Biotechnology peers
ROE
96.2%
▲
243%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
19.5%
▲
107%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
72.1%
▼
8%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
7.8%
▲
117%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
AMGN financial health vs Biotechnology peers
D/E ratio
567.5
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
1.3
▼
71%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
0.5
▼
52%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
AMGN fundamentals radar
AMGN
Peer median
Industry
AMGN profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
AMGN vs peers: key metrics
Latest AI Opinion
Grok
BUY
Price action shows a clear 10% pullback from the recent high of ~$385 (early March 2026) to the current $348.53, creating a compelling dip-buy entry point near prior support around $340-350 observed in late 2025/early 2026, with the low beta …
Mar 24, 2026Insider Activity
NeutralBuys
0
Sells
0
BRADWAY ROBERT A
Chief Executive Officer · Mar 04
119782 shs
GRAHAM JONATHAN P
General Counsel · Mar 03
10723 shs
GORDON MURDO
Officer · Mar 03
13403 shs
BRADWAY ROBERT A
Chief Executive Officer · Mar 03
42657 shs
GRIFFITH PETER H.
Chief Financial Officer · Mar 03
12063 shs
GRYGIEL NANCY A
Officer · Mar 03
2010 shs
KHOSLA RACHNA
Officer · Mar 03
1876 shs
MILLER DEREK
Officer · Mar 03
3484 shs
BUSCH MATTHEW C.
Officer · Mar 03
938 shs
REESE DAVID M.
Chief Technology Officer · Mar 03
12063 shs
Last 90 days
Top Holders
Top 5: 32.28%Vanguard Group Inc
10.17%
$19.1B
Blackrock Inc.
8.79%
$16.5B
State Street Corporation
5.67%
$10.7B
Capital World Investors
4.28%
$8.1B
Capital International Inves…
3.37%
$6.3B
As of Dec 31, 2025
Dividends
$9.66
/ year
Feb 13, 2026
$2.5200
Nov 21, 2025
$2.3800
Aug 22, 2025
$2.3800
May 16, 2025
$2.3800
Feb 14, 2025
$2.3800
Nov 18, 2024
$2.2500
Aug 16, 2024
$2.2500
May 16, 2024
$2.2500